Advertisement

Advertisement

2016 ASH Annual Meeting

Advertisement

Advertisement



Nov
13
Today In Oncology
Bendamustine/Rituximab Followed by Y-90 Ibritumomab Tiuxetan in Previously Untreated Follicular Lymphoma
Study Finds Nearly One in Four Oncologists Rarely or Never Mention Cost When Discussing Genomic Testing
Levofloxacin Prophylaxis During Treatment of Newly Diagnosed Multiple Myeloma
PROs Observed With Durvalumab Treatment After Chemoradiotherapy for Stage III Unresectable NSCLC
Factors Influencing Freedom From Distant Recurrence in Premenopausal Women With HR-Positive, HER2-Negative Breast Cancer
View More 
Advertisement
Most Read Stories
ctDNA and Recurrence Risk After Surgery and Adjuvant Chemotherapy for Stage III Colon Cancer
Levofloxacin Prophylaxis During Treatment of Newly Diagnosed Multiple Myeloma
Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial
Continuous Therapy for Multiple Myeloma Offers Survival Advantage, but Questions Remain
Outcomes in Patients With Early Breast Cancer and High 21-Gene Recurrence Score Treated With Adjuvant Chemotherapy Plus Endocrine Therapy: Secondary Analysis of TAILORx
View More 
Most Viewed Videos
David Routman, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV Circulating Tumor DNA
Andrew D. Zelenetz, MD, PhD, on The Era of Therapeutic Biosimilars: What You Need to Know
Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
Sungjune Kim, MD, PhD, on Merkel Cell Carcinoma: Nivolumab/Ipilimumab Plus SBRT
Martee L. Hensley, MD, on Leiomyosarcoma: Results From a GOG Treatment Trial
View More 
© 2019 HSP News Service, L.L.C.